v3.26.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Revenue:        
Total revenue $ 21,000 $ 18,000 $ 31,000 $ 25,000
Costs and expenses:        
Cost of revenue 6,000 1,000 8,000 2,000
Sales, general and administrative compensation (inclusive of stock-based compensation) 156,000 261,000 1,942,000 755,000
Sales and marketing 2,000 1,000 22,000
Professional Fees 96,000 234,000 446,000 868,000
Research and development 35,000 52,000 158,000 230,000
Depreciation and Amortization 284,000 288,000 853,000 859,000
Rent and utilities 19,000 19,000 55,000 56,000
Other operating expenses 73,000 109,000 207,000 345,000
Total costs and expenses 669,000 966,000 3,670,000 3,137,000
Operating loss (648,000) (948,000) (3,639,000) (3,112,000)
Other income (expense):        
Interest income 4,000 3,000 10,000 10,000
Change in fair value of note payable, related party (268,000) (13,210,000)
Interest expense (262,000) (793,000)
Loss from operations before income taxes (644,000) (1,475,000) (3,629,000) (17,105,000)
Income tax benefit
Net loss (644,000) (1,475,000) (3,629,000) (17,105,000)
Income (loss) from operations attributed to noncontrolling interest (1,000) 5,000 (3,000) 22,000
Net loss attributable to common stockholders $ (645,000) $ (1,470,000) $ (3,632,000) $ (17,083,000)
Loss per common share:        
Basic $ (0.08) $ (1.52) $ (0.43) $ (17.96)
Diluted $ (0.08) $ (1.52) $ (0.43) $ (17.96)
Shares used in computing loss per common share:        
Basic 8,544,066 965,607 8,543,137 951,292
Diluted 8,544,066 965,607 8,543,137 951,292
Biotech Retail Sales [Member]        
Revenue:        
Total revenue $ 21,000 $ 18,000 $ 31,000 $ 25,000